CA2471620A1 - Pyrrolidone carboxamides - Google Patents

Pyrrolidone carboxamides Download PDF

Info

Publication number
CA2471620A1
CA2471620A1 CA002471620A CA2471620A CA2471620A1 CA 2471620 A1 CA2471620 A1 CA 2471620A1 CA 002471620 A CA002471620 A CA 002471620A CA 2471620 A CA2471620 A CA 2471620A CA 2471620 A1 CA2471620 A1 CA 2471620A1
Authority
CA
Canada
Prior art keywords
rac
phenyl
carboxamide
oxopyrrolidine
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002471620A
Other languages
English (en)
French (fr)
Inventor
Markus Isler
Thomas Giller
Gunter Schwalm
Matthias Steger
Kurt Hilpert
Oliver Valdenaire
Volker Breu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2471620A1 publication Critical patent/CA2471620A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002471620A 2001-12-31 2002-12-27 Pyrrolidone carboxamides Abandoned CA2471620A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH23812001 2001-12-31
CH2381/01 2001-12-31
CHPCT/CH02/00429 2002-08-05
CH0200429 2002-08-05
PCT/CH2002/000725 WO2003059905A1 (de) 2001-12-31 2002-12-27 Pyrrolidon-carboxamide

Publications (1)

Publication Number Publication Date
CA2471620A1 true CA2471620A1 (en) 2003-07-24

Family

ID=25705687

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002471620A Abandoned CA2471620A1 (en) 2001-12-31 2002-12-27 Pyrrolidone carboxamides

Country Status (8)

Country Link
EP (1) EP1463724A1 (ja)
JP (1) JP2005521651A (ja)
KR (1) KR20040072697A (ja)
CN (1) CN100534990C (ja)
AU (1) AU2002350366A1 (ja)
CA (1) CA2471620A1 (ja)
MX (1) MXPA04006458A (ja)
WO (1) WO2003059905A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
ES2386365T3 (es) 2005-01-05 2012-08-17 Abbott Laboratories Derivados de adamantilo como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa de tipo 1
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
US20090036492A1 (en) * 2005-08-09 2009-02-05 Akihiro Furukawa Novel Cercosporamide Derivative
JP4726243B2 (ja) * 2005-08-09 2011-07-20 第一三共株式会社 新規セルコスポラミド誘導体
US7435833B2 (en) * 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
WO2011035332A1 (en) * 2009-09-21 2011-03-24 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators
CN102827056B (zh) * 2012-09-03 2014-07-23 华东理工大学 N-芳基取代吡咯烷酮衍生物及其用途
SG11201606619UA (en) * 2014-04-04 2016-09-29 Sanofi Sa Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US10968176B2 (en) 2014-09-14 2021-04-06 Nanosynthons Llc Pyrrolidone derivatives, oligomers and polymers
WO2016040962A1 (en) * 2014-09-14 2016-03-17 Nanosynthons Llc Pyrrolidone derivatives, oligomers and polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB856452A (en) * 1957-06-27 1960-12-14 Bayer Ag Protective agents against textile pests, mould and bacteria
US5281612A (en) * 1982-09-09 1994-01-25 Warner-Lambert Company Naphthyridine antibacterial agents
ES2087097T3 (es) * 1989-04-19 1996-07-16 Otsuka Pharma Co Ltd Derivados de acidos fenilcarboxilicos que contienen un heterociclo.
US6387932B1 (en) * 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists
AU6000900A (en) * 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
GB0010757D0 (en) * 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
CN100534990C (zh) 2009-09-02
MXPA04006458A (es) 2004-10-04
KR20040072697A (ko) 2004-08-18
JP2005521651A (ja) 2005-07-21
WO2003059905A1 (de) 2003-07-24
CN1610678A (zh) 2005-04-27
EP1463724A1 (de) 2004-10-06
AU2002350366A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
CA2471620A1 (en) Pyrrolidone carboxamides
JP3108719B2 (ja) 新規なn−アルキレンピペリジノ化合物及びそのエナンチオマー;これらを合成する方法及びこれらを含む医薬品組成物
AU2008206759B2 (en) Nicotinic acetylcholine receptor modulators
CN100383118C (zh) 4-吡咯烷基-苯基-苄基醚衍生物
RO121597B1 (ro) Derivati de 2-oxo-1-pirolidina, compozitii farmaceutice si utilizarea lor
CA2218548A1 (en) Xanthines and their therapeutic use
JP2007510702A (ja) 代謝性疾患の処置に有用な11−β−HSD1阻害剤としてのN−アシル化−3−(ベンゾイル)−ピロリジン
CA2491835A1 (en) Mch1r antagonists
JP2013508434A (ja) ポジティブアロステリックモジュレータ(pam)
WO2004022528A2 (en) Arylglycine derivatives and their use as glycine transport inhibitors
JP2003506437A (ja) 苦痛状態の治療のためのnmda−レセプターアンタゴニストとして有効な置換された1,5−ジヒドロピロール−2−オン誘導体
HU225111B1 (en) Aminomethylindans, -benzofuranes and-benzothiophenes and pharmaceutical compositions containing them
KR20000005505A (ko) 피페리딘 및 피롤리딘
CN112513032B (zh) 作为trk受体的调节剂的4-取代的苯基-1,3,5-三嗪衍生物
EP0299493B1 (en) N-[(2-Oxopyrrolidin-1-yl)-acetyl]piperazine derivatives and drug for senile dementia
CA2306477A1 (en) Azaring-ether derivatives and their use as nicotinic ach receptor modulators
US7067549B2 (en) Pyrrolidone carboxamides
FR2908766A1 (fr) Derives de pyrrole,leur preparation et leur utilisation en therapeutique.
US6395905B1 (en) Tetrahydroindazole derivatives as ligands for GABA-A α 5 receptors
RU2378270C2 (ru) Бензилокси-производные в качестве ингибиторов моноаминоксидазы b
RU2296757C2 (ru) Производные хиназолина
FR2911136A1 (fr) Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
TWI589571B (zh) 乙炔基衍生物
FR2676227A1 (fr) Nouveaux intermediaires pour la synthese de composes dialkylenepiperidino.
FR2676225A1 (fr) Nouveaux intermediaires pour la synthese de composes dialkylenepiperidino.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued